Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that enrollment in its Phase 3 APPROACH clinical trial evaluating HLP003 for the adjunctive treatment of major depressive disorder has surpassed 86% and remains on track. The study is one of the company’s Phase 3 trials supporting development of HLP003, its lead proprietary novel serotonergic agonist, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
The APPROACH study is part of Helus Pharma’s broader Phase 3 PARADIGM program, which also includes the EMBRACE study and the EXTEND long-term extension study. The company said the enrollment milestone supports its goal of reporting topline data from APPROACH in the fourth quarter of 2026 as it advances HLP003 toward potential commercialization for patients with major depressive disorder. To view the full press release, visit https://ibn.fm/Qpikw.
This milestone is significant because major depressive disorder affects millions worldwide, and current treatments often have limited efficacy or significant side effects. HLP003, a proprietary novel serotonergic agonist, is designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering a new mechanism for treating depression. The Breakthrough Therapy Designation from the FDA underscores the potential of HLP003 to address the large unmet need for people who suffer from depression.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company committed to developing proprietary NSAs – novel serotonergic agonists – that aim to provide durable improvements in mental health. The company is currently developing HLP003 in Phase 3 for major depressive disorder and HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland. For company updates, visit www.helus.com.
The APPROACH trial’s progress is a key indicator for investors and patients alike, as positive results could lead to a new treatment option for major depressive disorder. The company’s focus on novel serotonergic agonists represents a shift from traditional antidepressants, which often target monoamine systems. If successful, HLP003 could become a first-in-class therapy, potentially changing the treatment landscape for depression.
Helus Pharma’s development of HLP003 is part of a broader trend in mental health research toward compounds that promote neuroplasticity. By activating specific serotonin pathways, these molecules may help the brain form new connections, offering hope for patients who do not respond to existing treatments. The Phase 3 PARADIGM program is designed to generate the robust data needed for regulatory approval, and the 86% enrollment milestone suggests that the trial is progressing efficiently.
